405 related articles for article (PubMed ID: 32365759)
1. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
[TBL] [Abstract][Full Text] [Related]
2. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
[TBL] [Abstract][Full Text] [Related]
3. Reversing multidrug resistance by tyrosine kinase inhibitors.
He M; Wei MJ
Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
[TBL] [Abstract][Full Text] [Related]
4. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
Wang XK; Fu LW
Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
Wu S; Fu L
Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
[TBL] [Abstract][Full Text] [Related]
10. Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors.
Fruci D; Cho WC; Nobili V; Locatelli F; Alisi A
Curr Drug Metab; 2016; 17(4):308-16. PubMed ID: 26694726
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Shukla S; Chen ZS; Ambudkar SV
Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
[TBL] [Abstract][Full Text] [Related]
12. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
[TBL] [Abstract][Full Text] [Related]
14. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
15. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
[TBL] [Abstract][Full Text] [Related]
17. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
Mohammad IS; He W; Yin L
Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
[TBL] [Abstract][Full Text] [Related]
18. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Karthikeyan S; Hoti SL
Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
[TBL] [Abstract][Full Text] [Related]
19. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
